Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...

The lower hinge of immunoglobulin G (IgG), an overlooked part of the antibody, acts as a structural and functional control hub, according to a study by researchers at Science Tokyo. Deleting a single ...

Deleting a single amino acid (Pro230) in the lower hinge produced half-IgG1 molecules with disrupted disulfide bonds and reoriented Fab and Fc regions, highlighting the hinge’s essential role in ...

Cancer scientists engineer a new type of antibody which could be used to boost the immune systems of patients fighting disease. Cancer scientists say they have engineered a new type of super-strong ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in ...

Age, biological sex, and human genetic factors influence the production of antibodies during the immune response. A team of scientists from the Institut Pasteur, the CNRS and the Collège de France ...

In the ever changing biotherapeutics landscape, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) success ...